2-Guanidinoacetic acid
(Synonyms: 胍基乙酸,Guanidinoacetic acid) 目录号 : GC33645
A metabolite of glycine and precursor in the biosynthesis of creatine
Cas No.:352-97-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Glycocyamine is a metabolite of glycine and precursor in the biosynthesis of creatine.1,2 It is formed from glycine by glycine amidinotransferase (GATM) in the kidney and pancreas, transported to the liver, and methylated by guanidinoacetate N-methyltransferase (GAMT) to form creatine.1 Levels of glycocyamine are altered in individuals with cerebral creatine deficiency syndromes (CCDSs), inborn errors of metabolism characterized by deficiencies in GATM or GAMT.3
1.Ostojic, S.M.Cellular bioenergetics of guanidinoacetic acid: The role of mitochondriaJ. Bioenerg. Biomembr.47(5)369-372(2015) 2.Portocarero, N., and Braun, U.The physiological role of guanidinoacetic acid and its relationship with arginine in broiler chickensPoult. Sci.100(7)101203(2021) 3.Stockler, S., Schutz, P.W., and Salomons, G.S.Cerebral creatine deficiency syndromes: Clinical aspects, treatment and pathophysiologySubcell. Biochem.46149-166(2007)
| Cas No. | 352-97-6 | SDF | |
| 别名 | 胍基乙酸,Guanidinoacetic acid | ||
| Canonical SMILES | O=C(O)CNC(N)=N | ||
| 分子式 | C3H7N3O2 | 分子量 | 117.11 |
| 溶解度 | 1M HCl: 50 mg/mL (426.95 mM; ultrasonic and adjust pH to 1 with HCl); Water: < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 8.539 mL | 42.6949 mL | 85.3898 mL |
| 5 mM | 1.7078 mL | 8.539 mL | 17.078 mL |
| 10 mM | 0.8539 mL | 4.2695 mL | 8.539 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Multidentate Chelation Heals Structural Imperfections for Minimized Recombination Loss in Lead-Free Perovskite Solar Cells
Angew Chem Int Ed Engl 2022 Oct 4;61(40):e202209464.PMID:35982524DOI:10.1002/anie.202209464
Tin-based perovskite solar cells (Sn-PSCs) have emerged as promising environmentally viable photovoltaic technologies, but still suffer from severe non-radiative recombination loss due to the presence of abundant deep-level defects in the perovskite film and under-optimized carrier dynamics throughout the device. Herein, we healed the structural imperfections of Sn perovskites in an "inside-out" manner by incorporating a new class of biocompatible chelating agent with multidentate claws, namely, 2-Guanidinoacetic acid (GAA), which passivated a variety of deep-level Sn-related and I-related defects, cooperatively reinforced the passivation efficacy, released the lattice strain, improved the structural toughness, and promoted the carrier transport of Sn perovskites. Encouragingly, an efficiency of 13.7 % with a small voltage deficit of ≈0.47 V has been achieved for the GAA-modified Sn-PSCs. GAA modification also extended the lifespan of Sn-PSCs over 1200 hours.